Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Bioxyne Limited ( (AU:BXN) ) has issued an update.
Bioxyne Limited will present at the NWR Virtual Healthcare Conference, with Executive Director Jason Hine scheduled to deliver an investor-focused update via a virtual session, which will be accessible live and later as a recording. The appearance provides the ASX-listed pharmaceutical group and its Breathe Life Sciences subsidiary an additional platform to showcase their expanding presence in alternative therapeutics, controlled-substance manufacturing and international distribution to current and prospective stakeholders.
Breathe Life Sciences underpins Bioxyne’s strategy as a GMP-licensed manufacturer and distributor of controlled medicines, including medicinal cannabis, psilocybin and MDMA, with operations in Australia, Japan, the U.K. and Czechia supporting a range of pharmaceutical, consumer health and novel food products. The conference participation may help reinforce Bioxyne’s positioning as a market leader in Australian therapeutic goods based on cannabis and psychedelics, while highlighting its vertically integrated model spanning manufacturing, white-label production, research and branded offerings such as the Dr Watson line across multiple international markets.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.
More about Bioxyne Limited
Bioxyne Limited is an Australian pharmaceutical company focused on developing and commercialising innovative medicines and active pharmaceutical ingredients, with a growing emphasis on psychedelic compounds for therapeutic use. Through its wholly owned subsidiary Breathe Life Sciences, it operates a multinational, GMP-licensed platform spanning medicinal cannabis, MDMA, psilocybin and other controlled substances across Australia, the U.K., Europe and Japan.
Average Trading Volume: 3,248,363
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$113.5M
For detailed information about BXN stock, go to TipRanks’ Stock Analysis page.